What are the recommended management options and medication regimens for symptomatic or progressive meningioma, including surgery, radiotherapy, corticosteroids, hydroxyurea, temozolomide, bevacizumab, and somatostatin analogs?

Meningioma Management and Medications

For symptomatic or progressive meningiomas, surgery remains first-line treatment, followed by radiotherapy for incompletely resected or high-grade tumors; for recurrent/refractory disease after maximal local therapy, bevacizumab shows the most promising activity with 86% 6-month progression-free survival, while SSTR2-targeted peptide receptor radionuclide therapy (PRRT) with [177Lu]DOTATATE represents an emerging option for SSTR2-expressing tumors. 1, 2, 3

Primary Management Algorithm

Initial Treatment Sequence

Surgery is the cornerstone for most meningiomas at diagnosis. The goal is maximal safe resection when feasible 1.

Postoperative radiotherapy should be considered based on:

• Extent of resection (incomplete resection)
• Histological grade (WHO grade 2 or 3)
• Molecular features indicating higher recurrence risk 1

Recurrent/Progressive Disease After Local Therapies

When further surgery and radiotherapy are exhausted, systemic therapy becomes necessary 1, 4.

Systemic Therapy Options

Most Promising: Anti-Angiogenic Therapy

Bevacizumab demonstrates the strongest clinical evidence among systemic agents:

• 86% progression-free survival at 6 months 2
• Effective as monotherapy or combined with chemotherapy 2
• Comparable efficacy across meningioma grades 2
• Generally well-tolerated, though monitor for CNS hemorrhage and intestinal perforation 2

Other anti-angiogenic agents (sunitinib, vatalanib) show potential but have less robust data 5, 4, 6.

Emerging: SSTR2-Targeted Radioligand Therapy

For tumors with high SSTR2 expression (which characterizes most meningiomas), PRRT with [177Lu]DOTATATE or [90Y]Yttrium offers a theranostic approach 3, 7, 8:

Pre-treatment imaging with [68Ga]DOTATATE PET is essential to:

• Confirm SSTR2 expression levels
• Identify suitable candidates for PRRT
• Provide superior tumor delineation compared to MRI alone 3

PRRT shows encouraging results in treatment-refractory meningiomas 3, 7, though randomized trials are lacking and it remains unapproved by FDA/EMA 3.

Clinical response correlates strongly with:

• WHO tumor grade
• SSTR2 expression density 8

Limited Efficacy Options

The following have minimal evidence supporting their use 1, 5, 4, 6:

Hydroxyurea 9:

• Recognized in guidelines as an option 6
• Limited efficacy in practice 4
• Dose reduction required if creatinine clearance <60 mL/min 9

Temozolomide 10:

• FDA-approved for glioblastoma, not meningioma
• Limited efficacy in meningioma 4

Somatostatin analogs (octreotide, pasireotide):

• Modest efficacy at best 5, 6, 11
• May offer last-option treatment for severely ill patients 11
• Sparse adverse effects 11

Hormonal therapies (mifepristone, megestrol acetate):

• Generally ineffective 4, 12

Classical chemotherapy (cyclophosphamide/adriamycin/vincristine, irinotecan):

• Limited efficacy 4, 12

Investigational Targeted Therapies

No molecular target has reached ESCAT I (ready for clinical use) classification 1. Only mTOR pathway activation and NF2 alterations reached ESCAT II (investigational) 1.

Agents under investigation include 5, 4, 7:

• mTOR inhibitors
• FAK inhibitors
• CDK4/6 inhibitors
• PI3K inhibitors
• SMO inhibitors (for SMO-mutant tumors)
• Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab)

Critical limitation: Most driver mutations are present only in subsets of meningiomas, requiring molecular profiling for patient selection 7.

Corticosteroids

Use corticosteroids for symptomatic management of peritumoral edema and mass effect, not as anti-tumor therapy. Taper as clinically appropriate.

Key Clinical Pitfalls

• Do not delay surgery/radiotherapy in favor of systemic therapy for operable tumors—local control is superior
• Molecular profiling is increasingly important but most targeted therapies remain investigational 1
• SSTR2 PET imaging should precede PRRT consideration to confirm receptor expression 3
• Most patients are heavily pre-treated before systemic therapy, which may affect response rates 2
• Bevacizumab carries specific risks: monitor for hemorrhage and bowel perforation 2

Evidence Quality Context

The evidence base for systemic therapy in meningioma is weak overall—no prospective randomized controlled trials with high-level evidence exist 4. Most data comes from small retrospective series and single-arm phase 2 trials. The 2025 EANO guideline emphasizes that no targeted treatments are approved for meningioma, though off-label use may be considered based on molecular screening 1.